Check out your Company Bowl for anonymous work chats.
Almac Group releases details of £80 million expansion in Northern Ireland October 19, 2023 Expansion will create 550 jobs in 140,000ft2 development and manufacturing facilities The Almac Group has today announced details of an £80 million investment programme to build new extensive manufacturing, production and diagnostic laboratory facilities at its Global Headquarters in Craigavon, Northern Ireland. The construction of these two significant facilities will create over 550 jobs locally, spanning a range of lab and non-lab-based roles, with recruitment already commenced for some positions. This is part of the company’s international recruitment drive which is expected to create 1,000 jobs in Northern Ireland over three years. The expansion, which is part of the global investment programme announced in 2022, will significantly grow operations for two of the Group’s business units, Almac Pharma Services and Almac Diagnostic Services. Almac Pharma Services supports the development and commercialisation of new treatment options for a wide range of therapy areas including oncology and immunology. Almac Diagnostic Services offers a range of biomarker discovery, development and commercialisation solutions to Biopharma partners globally.
Almac Diagnostic Services, a member of the Almac Group, has announced investment to expand its Next Generation Sequencing (NGS) capabilities for BioPharma partners, following the purchase and installation of the first Illumina NovaSeq™ X Plus instrument in Northern Ireland and the whole island of Ireland. This investment in the newest and most powerful instrument from Illumina enhances Almac’s NGS portfolio of DNA Sequencing Service offerings, including Whole Genome Sequencing, Whole Exome Sequencing and a range of RNA Sequencing Service offerings for Biomarker Discovery projects. Adding the Illumina NovaSeq X Plus’s powerful processing capabilities to Almac’s existing range of NGS platform offerings will enable even larger sample runs, greater read depth, including both short and long-read sequencing and faster speeds. As a result, it will increase throughput, variant detection quality and accuracy, while reducing turnaround time and cost per sample for client biomarker research projects. Michael Sloan, Global VP of Commercial Operations, Almac Diagnostic Services said: “Almac is at the cutting edge of NGS diagnostics. Investing in this new instrument further enhances our DNA and RNA panel offerings, opens the potential for further expansion of our NGS solutions for clients and significantly increases overall sequencing capacity, ensuring that Almac continues to play a leading role within precision medicine.”
Almac Group grows by 150, exceeding 500 total headcount in Durham August 30, 2023 Corporate investment and client demand leads to growth in headcount by more than a third in two years. Almac Group, the global contract development and manufacturing organisation, today celebrates that the company has exceeded 500 employees at its Durham, North Carolina location. This organic growth has led to 150 new employees joining the company since 2021, an over 30% increase in total headcount for the site. Almac’s rapid growth in Durham is solely as result of inward investment and increased client demand for the company’s market – leading clinical and diagnostic services offered at the site. Since taking occupancy at the technology park in 2000, Almac has more than doubled capacity, now spanning four buildings on the campus totaling 150,000 ft2. Almac is a privately owned, Northern Ireland – based company that re-invests all profits back into its business. The company has continued to demonstrate a commitment to the growth and stability of its North Carolina operations by launching a number of specialist capabilities for the Group at the site since its inception. These investments over the years have included significant capacity expansions for clinical supply services, the opening of diagnostic laboratory, the launch of an innovative temperature monitoring system for clinical supplies, and the addition of ultra-cold and Cryogenic clinical services capabilities to meet the demands
Almac Group marks groundbreaking of $65 million facility expansion in Montgomery County August 7, 2023 Capital growth project expands Souderton campus by nearly 50% of current footprint and brings 355 local jobs to the region. Almac Group, the global contract development and manufacturing organisation, today marks the ceremonial ground breaking of a $65 million expansion project on the company’s North American headquarters campus in Souderton, PA. This expansion is a strategic investment in Cold Chain Operations, Just-In-Time Processing, and Analytical Testing capabilities. These are crucial to supporting the development of Advanced Therapeutic Medicinal Products (ATMPs). As previously announced in August 2022, the expansion will yield a 60% increase in capacity for Almac’s clients, supported with a projected total of 355 new jobs by 2026.
Almac Group opens a new custom-built GMP warehouse at its Global Headquarters Almac Sciences, a member of the Almac Group, has officially opened a new custom-built GMP warehouse and dispatch hub at its Global Headquarters in Craigavon, UK. The new 19,500 square foot facility consolidates the existing warehouses and supply chain offices and will provide support to all Active Pharmaceutical Ingredient (API) manufacturing and laboratory activities, from development to commercialisation.
Almac Group Wins Life Sciences Team of the Year Almac Sciences, a member of the Almac Group, is delighted to announce a win in the Life Sciences Team of the Year category during this year’s Irish Life Sciences Awards ceremony, held on 6 July 2023 at Crowne Plaza Hotel, Dublin. Almac Sciences’ Technology Group was selected as the winner of the “Life Sciences Team of the Year” category. The Technology Group is a multi-disciplinary team, offering a toolbox of innovative technology solutions for synthetic chemistry including biocatalysis, biology services, custom and flow chemistry, radiochemistry and physical sciences right through to manufacture on tonne scale.
Almac’s global workforce has reached 7,000 people! More than 1,000 new employees have joined us in the last 18 months. Our people are at the core of everything we do. Thanks to the hard work and dedication of our growing workforce over the past year, Almac has been involved in the development of hundreds of life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy and neurology. Read more: https://hubs.li/Q01SChGY0
Almac Group employees raise £50,000 through an annual draw for two local children’s charities, Angel Wishes and the Children’s Heartbeat Trust. Angel Wishes supports children and their families throughout Northern Ireland who are diagnosed with cancer-related conditions. This is a volunteer-led charity with 100% of all proceeds raised through fundraising and donations going directly into providing much-needed support. Since 1984 the NI Children’s Heartbeat Trust has been providing practical, emotional, and financial support to children and young people living with heart disease and their families. The generous donations from Almac employees will enable these charities to continue to provide invaluable support to young people and their families across Northern Ireland. The cheques were presented by Elaine Gibson, Global Travel and Events Manager, to Samantha Coleman from the Children’s Heartbeat Trust and Gaye Kerr from Angel Wishes.
Almac Group, the global contract pharmaceutical development and manufacturing organisation, has today (Tuesday 14th June) reported its highest ever end-of-year results for revenue, profit, and employee numbers. In their financial results for year ending 30 September 2021, Almac recorded a £58 million (8.6%) rise in turnover from £677 million in 2020 to £735 million in 2021. Pre-tax profits were recorded at £81 million, up from £64 million (27.1% increase) for the same period the previous year. The report also detailed an increase in Almac’s average employee figures from 5,466 to 5,783 (5.8%) during the period of October 2020 to September 2021. Current employee numbers for the Group now sits at over 6,500 and a current global recruitment drive will increase the total number to over 8,000 over the next three years, with over 1,000 of these new roles planned for Northern Ireland.
Almac Group is at the forefront of developing, manufacturing, testing and distributing essential medicines to vulnerable patients around the world. Headquartered in Craigavon, Almac employs over 6,000 highly skilled personnel in 19 facilities across the globe including Europe, the US and Asia, over 3,600 of whom are in Northern Ireland. Sustainability and protecting our employees, clients and communities is central to Almac Group’s ethos. We are committed to being good global neighbours by reducing our own environmental footprint and through the development of green technology to ensure that together with our clients, we achieve a low-carbon future.
